A Phase 1 interventional study of DWP14012 Amg and DWP14012 Bmg in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-26.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after administrations of DWP14012 alone and combinations of DWP14012, Clarithromycin and Amoxicillin in healthy male subjects
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin
Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin
Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin
Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin
Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
Drug: DWP14012 Bmg · Drug: Clarithromycin · Drug: Amoxicillin
Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin
Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
Drug: Clarithromycin · Drug: Amoxicillin · Drug: Lansoprazole
DWP14012 Amg
DWP14012 Bmg
Clarithromycin 500 mg
Amoxicillin 1 g
Lansoprazole 30 mg
Cmax,ss: Maximum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
Cmin,ss: Minimum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
Cav,ss: Average concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
AUCt,ss: Area under the drug concentration-time curve within a dosing interval at steady states
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
Tmax,ss: Time of maximum concentration at steady state
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
T1/2: Elimination half-life
Part I: each period (Group A, B, C, D) Part II: Group A, B
Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours
Percentage of total time that the intragastric pH was above 4
Part I
Time frame: Period 1 Day -1 and Group A, C Day 7 0~24 hours
Percentage of total time that the intragastric pH was above 4
Part II
Time frame: Day -1, Day 1, Day 7 0~24 hours
Percentage of total time that the intragastric pH was above 6
Part I
Time frame: Period 1 day -1 and Group A, C Day 7 0~24 hours
Percentage of total time that the intragastric pH was above 6
Part II
Time frame: Day -1, Day 1, Day 7 0~24 hours
Serum gastrin concentration profile
Part I
Time frame: Period 1 Day -1 and Group A, C Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours
Serum gastrin concentration profile
Part II
Time frame: Day -1 pre-dose, 2, 4, 6, 8, 12 hours, Day 1 and 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours
Number of participants with Adverse Events (AE)
All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate and severe
Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)
Number of Participants With Clinically Significant Vital Sign findings
Blood pressure(mmHg), pulse (beats/min) and body temperature(℃) were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.
Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)
Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings
Ventricular rate(beats/min), RR, PR interval(msec), QRS duration(msec), QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).
Time frame: Day -2 (Randomization) to Day 54~60 (Post-study visit of Part I) and Day 36~42 (Follow up visit of Part II)
Number of Participants With Clinically Significant Laboratory results
Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.
Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)
Ran from Apr 2018 to primary completion in Jan 2019, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →